Aktiia’s automated Optical Blood Pressure Monitoring System for 24-7 use at the wrist reports accelerating sales growth in the United Kingdom, Ireland, Germany, Austria, Switzerland, France and Italy. The funds will be used to fuel growth in these markets and to obtain FDA clearance.
Draper Esprit leads the US$ 17.5m Series A investment in hypertension health-tech firm Aktiia. Additional Investors participating in the round include 415 Capital, Redalpine Venture Partners, Verve Ventures and Silicon Valley-Based Translink Capital.
The new capital will be used to expand Aktiia’s commercial footprint in the NHS and key healthcare markets across Europe and to build out a team focusing on the healthcare channel. A percentage of the Series A funds will also go towards obtaining FDA clearance to enable expansion to the US market, following Aktiia's reception of the CE Mark as a Class IIa medical device in Europe, signifying that the device has been assessed to meet high safety, health and environmental protection requirements.
Dr Inga Deakin, principal, Draper Esprit said: “Aktiia has built a rigorously tested, non-invasive, automated blood pressure monitoring system at the wrist, providing a comprehensive, longitudinal picture of hypertension in patients. Their strong clinical validation, patient engagement, and market traction are extremely impressive and give us every confidence that Aktiia will transform how hypertension is measured and managed globally.”
Professor Melvin Lobo, NHS Professor of Cardiovascular Medicine and Director of St. Bartholomew’s Hospital Blood Pressure Clinic commented: “I believe we are only scratching the surface of the possible applications for the long-term 24/7 blood pressure data that Aktiia is uniquely capable of providing to physicians. This is an indisputable game changer in enabling a better understanding of our patients’ blood pressure patterns and how to treat them on a personalized basis.”
(Press release / SK)
Please login or sign up to comment.
Commenting guidelines